Dolphin 'therapy' a dangerous fad, Emory resear...(tail flukes and take them away. Eac...)
Navigation Links
Dolphin 'therapy' a dangerous fad, Emory researchers warn
Date:12/18/2007
tail flukes, and take them away."
Each live dolphin can bring a fisherman $50,000 or more, she says. "The marine parks make millions off of dolphins, so that's a drop in the bucket. It's an irony that dolphins are among the most beloved, and the most exploited, animals in the world," Marino says.
'/>"/>
| Contact: Beverly Clark beverly.clark@emory.edu 404-712-8780 Emory University Source:Eurekalert |
Related biology news :
1. Baiji Dolphin previously thought extinct spotted in the Yangtze River
2. Migrating squid drove evolution of sonar in whales and dolphins, researchers argue
3. Scientists fear rare dolphin driven to extinction by human activities
4. A new radiation therapy treatment developed for head and neck cancer patients
5. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
6. UC health news: molecular pathway may predict chemotherapy effectiveness
7. MIT works toward safer gene therapy
8. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
9. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
10. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
11. Safe and effective therapy discovered for patients with protein-losing enteropathy
Post Your Comments:
Breaking Biology News(10 mins):Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2Genome BC collaborates with Chile and Norway to sequence salmon genome 2A virtual physician's conference 2Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches 6621 1Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches 6621 2Childhood Lead Exposure Causes Permanent Damage 3A Study 62342 1Childhood Lead Exposure Causes Permanent Damage 3A Study 62342 2Cardiovascular risk in youth with type 1 diabetes linked primarily to insulin resistance 62337 1Cardiovascular risk in youth with type 1 diabetes linked primarily to insulin resistance 62337 2
Other Biology News:Carnegie Mellon receives $1.85 million 2Genes and environment interact in first graders to predict physical but not social aggression 2Want healthy gums? Hit the dairy aisle 2
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6
[0] BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines[0] Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery[0] Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Other Biology Technology:Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 2Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |